Rheumatoid Arthritis News

In patients with rheumatoid arthritis who failed to respond to TNF inhibitors, olokizumab is effective and carries an acceptable safety risk, especially when paired with methotrexate, according to data published in Clinical Rheumatology.

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.

Integrative medicine approaches such as tai chi and yoga, which have long been used in rheumatology in a secondary or supplementary role, are increasingly being viewed as essential care.

Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.

Mandatory switching policies for biosimilars are “much more” effective in increasing adoption than focusing on new start strategies, according to a study of Canadian health spending data published in Arthritis Care & Research.

Long-term sarilumab therapy for rheumatoid arthritis demonstrates no new safety outcomes regardless of concurrent use of conventional synthetic disease-modifying antirheumatic drugs, according to data published in Rheumatology.

Rheumatoid arthritis is independently associated with incident HF across the range of ejection fraction, with a stronger association among those with an EF of at least 40%, researchers reported.

Older patients with rheumatic diseases are less to report “vigorous” levels of physical activity, compared with other age groups, which may lead to more lifestyle difficulties, according to data published in The Journal of Rheumatology.

Adverse events and outcomes are more common in pregnant patients with rheumatoid arthritis and systemic lupus erythematosus, and their infants, vs. those without rheumatic diseases, according to data published in Arthritis Care & Research.

Patients with rheumatoid arthritis who consume alcohol report lower baseline disease activity and more favorable 1-year outcomes than those who abstain, according to data published in Arthritis & Rheumatology.